US Tariffs on Pharmaceutical Products from Chile — 10% (2026)

Among US trading partners for pharmaceutical products, Chile plays a notable role, with approximately $30B in total bilateral trade.

As of March 2026, pharmaceutical products imports from Chile face a base tariff rate of 10% under Section 122 of the Trade Act of 1974. This rate replaced the previous IEEPA reciprocal tariff following the Supreme Court's 6-3 ruling in V.O.S. Selections Inc. v. United States on February 20, 2026.

Under the Trade Act of 1974, Section 122 tariffs are limited to 150 days. The current 10% rate expires around July 24, 2026. Congressional action would be required to extend these tariffs beyond that date.

Pharmaceutical Products (HTS Chapter 30) generally enter duty-free at the MFN level, with the Section 122 tariff as the primary duty. No additional Section 232 or Section 301 surcharges apply to most products in this category from Chile.

Chile is party to the US-Chile FTA, which may provide preferential or duty-free access for qualifying pharmaceutical products. Importers should verify rules of origin requirements to take advantage of preferential rates.

Key products in HTS Chapter 30 imported from Chile include Vaccines, Antibiotics, Insulin, Bandages, Diagnostic reagents, and Blood products.